[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334315-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334315-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","medicine-availability-and-affordability-for-paediatric-cancers-china","Medicine availability and affordability for paediatric cancers, China","","Research addresses access to essential anticancer medicines for children across China, focusing on both availability and affordability. Cross-sectional 2021 drug-use data from 55 tertiary children’s hospitals in seven regions were analyzed, using a WHO Model list of 33 medicines. Availability was estimated by hospital coverage, while affordability compared single-day copayments or treatment-course costs against regional daily disposable income. Although all medicines were approved, availability and cost burdens remained uneven by region and medicine type.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/medicine-availability-and-affordability-for-paediatric-cancers-china/334315/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/medicine-availability-and-affordability-for-paediatric-cancers-china/334315.png","ImageObject",300,407,{"name":42,"@type":43},"Theodora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s objective?","Question",{"text":63,"@type":64},"To investigate access to essential anticancer medicines for children throughout China, evaluating both availability and affordability across regions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were availability and affordability assessed?",{"text":68,"@type":64},"Availability was calculated from cross-sectional drug use data across hospitals. Affordability compared single-day copayments (or treatment-course costs) with regional daily disposable income.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings about availability and affordability?",{"text":72,"@type":64},"Even though all medicines were approved in China, 14 medicines were available in under half of hospitals, and some products had copayments exceeding daily disposable income. Only 42.4% had both good availability and affordability, with the lowest proportion in north-west China.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334315,1790064673,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Research   \nMedicine availability and affordability for paediatric cancers, China  \nLin Bai,a Tao Huang,a Huangqianyu Li,b Luwen Shi,a Avram Denburg,b Sumit Guptab & Xiaodong Guana  \n\n| Objective To investigate access to essential anticancer medicines for children throughout China.\u003Cbr>Methods We obtained cross-sectional drug use data for 2021 from 55 tertiary children's hospitals in seven geographical regions (one third of public children's hospitals in mainland China) . Affordability was assessed by comparing the single-day copayment for each medicine with the same generic name and route of administration (i. e. product) or for a treatment course with daily disposable income per capita in each region. The median availability and affordability of all 33 anticancer medicines in the 2021 WHO Model list of essential medicines forchildren were calculated and compared by region and medicine type.\u003Cbr>Findings Although all medicines had been approved in China, 14 (42 .4%) were available in under 50% of hospitals and six (18 . 2%) products had a median single-day copayment exceeding daily disposable income. Median availability was higher among the 19 medicines with approval for paediatric indications than among the 14 without (80 .0% versus 48. 2%, respectively; P \u003C 0.001) . Overall, 42.4%(14/33) of medicines had both good availability and affordability; the lowest proportion was in north-west China (30 . 3%, 10/33) . A Chinese resident needed to work for 5.3 days to afford 4 weeks’ induction therapy for acute lymphoblastic leukaemia, the most common childhood cancer. Conclusion Access to essential anticancer medicines for children remained suboptimal in China and varied across regions. Fewer than half the medicines studied had both good availability and affordability. Actions are warranted to address potential shortages and decrease the financial burden on families. |  |\n| --- | --- |\n| | |\n| Introduction | national availability and affordability of essential anticancer |\n| Cancer is a major cause of death among children and its | medicines for children in China. |\n| incidence is growing worldwide.1–3 Globally, there are large variations in childhood cancer survival rates, which range | Methods |\n| from under 30% in many low-and middle-income countries to around 80% in high-income countries, partly due to unequal | Data sources |\n| access to quality care and pharmacotherapy.3–5 As a result, | The National Health Commission of China established the |\n| in 2018 the World Health Organization (WHO) established | National Hospital Drug Use Monitoring System in 2016. |\n| the Global Initiative for Childhood Cancer, which aims to | This system requires public hospitals to report drug use |\n| increase cancer survival rates among children worldwide to | data every year, including the generic name of each drug, |\n| at least 60% by 2030 and to provide a foundation for national | its formulation and cost and the quantity used. For this |\n| initiatives on improving survival rates.6 As access to essential | study, we extracted cross-sectional data on drug use in 2021 |\n| medicines is critical for childhood cancer survival,7 WHO has | for 55 tertiary children's hospitals, which represented one |\n| continuously updated its Model list of essential medicines for | third of all public children's hospitals in mainland China. |\n| children every 2 years since 2007 to help national and regional | Hospitals were divided into seven geographical regions: |\n| authorities, especially those in resource-constrained settings, | east, south, central, north, north-west, south-west and |\n| select essential medicines with comparable efficacy and safety.8 | north-east China (online repository).18, 19 The central region |\n| Nonetheless, ensuring the availability and affordability of | comprised Henan, Hubei and Hunan; the south region com- |\n| essential medicines remains a challenge for low-and middle- | prised Guangdong, Guangxi and Hainan; the north region |\n| income c","cbCaikjkwYIWaefR","https://ap.wps.com/l/cbCaikjkwYIWaefR","pdf",1230858,15,"English","# Objective\n# Methods\n## Data sources\n## Study design and assessment\n# Findings\n# Conclusion\n# Actions","[{\"question\":\"What was the study’s objective?\",\"answer\":\"To investigate access to essential anticancer medicines for children throughout China, evaluating both availability and affordability across regions.\"},{\"question\":\"How were availability and affordability assessed?\",\"answer\":\"Availability was calculated from cross-sectional drug use data across hospitals. Affordability compared single-day copayments (or treatment-course costs) with regional daily disposable income.\"},{\"question\":\"What were the key findings about availability and affordability?\",\"answer\":\"Even though all medicines were approved in China, 14 medicines were available in under half of hospitals, and some products had copayments exceeding daily disposable income. Only 42.4% had both good availability and affordability, with the lowest proportion in north-west China.\"}]","Medicine availability and affordability for paediatric cancers, China | PDF",1790006243,38]